Document:

exv10w2

Exhibit 10.2

Waiver, Release and Option Agreement for Taribavirin

This Waiver, Release and Option Agreement for Taribavirin (the “Agreement”) is entered into and
made effective as of the latest date of signature appearing below (the “Effective Date”) by and
between Valeant Pharmaceuticals International, a Delaware corporation having offices located at One
Enterprise, Aliso Viejo, California 92656 (“Valeant”), Schering Corporation, a New Jersey
corporation having offices located at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033
(“Schering”) and Schering-Plough Ltd., a Swiss corporation having offices located at Weystrasse 20,
6000 Lucerne 6, Switzerland (together with Schering referred to herein as “SP”). (Each of SP and
Valeant is referred to from time to time herein individually as a “Party” or collectively as the
“Parties”.)

WHEREAS, SP and Valeant (as successor in interest to ICN Pharmaceuticals, Inc. and RibaPharm, Inc.)
are parties to that certain Agreement, dated November 14, 2000, (the “November 2000 Agreement”)
which grants SP certain rights of first and last refusal with respect to certain products being
developed by Valeant and/or its Affiliates, and

WHEREAS, Valeant is developing a proprietary product known as Taribavirin (as defined below) and
desires to grant exclusive licenses to develop and commercialize Taribavirin to one or more
independent third parties, and

WHEREAS, Valeant desires, and SP is willing to grant, a waiver and release from all of SP’s rights
of first and last refusal under the November 2000 Agreement with respect to Taribavirin on the
terms and conditions set forth in this Agreement,

NOW, THEREFORE, in consideration of the above and the mutual covenants set forth in this Agreement
and other valuable consideration the sufficiency of which is hereby acknowledged by the Parties,
the Parties agree as follows:

1. Definitions. All capitalized terms used in this Agreement (whether in the singular or plural)
shall have their respective meanings as set forth herein, including without limitation the
following:

1.1 “Affiliate” shall mean, with respect to each Party, any entity that directly or
indirectly controls, is controlled by, or is under common control with, such Party, where
control means the direct or indirect ownership of more than fifty percent (50%) of the
outstanding voting securities of an entity, or such other relationship as results in actual
control over the management, assets, business and affairs of an entity.

1.2 “F&LR Rights” shall mean all of the rights, options and other interests granted to SP
and its Affiliates under Sections 5.1 and 5.2 of the November 2000 Agreement.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

 

1.3 “Japan License Agreement” shall have the meaning set forth in Section 3 of this
Agreement.

1.4 “Japan Option” shall have the meaning set forth in Section 3 of this Agreement.

1.5 “Japan Option Term” shall mean the period beginning on the Effective Date and ending on
the earlier of: (i) thirty (30) calendar days after [**]; or (ii) the date on which Schering
notifies Valeant that SP is exercising the Japan Option.

1.6 “Taribavirin” shall mean the compound known as taribavirin, any solvates (including
without limitation hydrates), acids, bases, esters, salts, isomers, stereoisomers,
racemates, enantiomers, tautomers, polymorphs and crystalline forms of any of the forgoing.
For the avoidance of doubt, [**] are excluded from the definition of Taribavirin.

1.7 “Territory” shall mean all of the countries and territories in the world except for
Japan.

2. Waiver and Release of Rights. SP (acting on behalf of itself, its Affiliates and its and their
successors in interest) hereby expressly and irrevocably waives and releases all rights, options
and other interests held by SP and/or its Affiliates under the November 2000 Agreement with respect
to Taribavirin, including without limitation the F&LR Rights as applied to Taribavirin. The
Parties acknowledge and agree that on and after the Effective Date, and subject to Sections 3, 4
and 5 of this Agreement, Valeant and its Affiliates shall be free to license or otherwise dispose
of any and all rights, title and interest with respect to Taribavirin in the Territory without any
further obligations to SP and/or its Affiliates.

3. Japan Option Rights. Valeant hereby grants to Schering the irrevocable exclusive option during
the Japan Option Term to obtain an exclusive license to develop and commercialize Taribavirin
products in Japan (the “Japan Option”).

4. Exercise of Japan Option. Schering shall have the right, exercisable in its sole discretion, to
exercise the Japan Option rights at any time during the Japan Option Term by providing Valeant with
written notice to that effect. Upon receipt of such notice, Valeant and Schering (or its
designated Affiliate) shall promptly negotiate and enter into an exclusive license agreement for
Taribavirin in Japan (the “Japan License Agreement”). The Japan License Agreement shall expressly
include the terms and conditions set forth in Appendix 1 (attached to this Agreement) and
such other reasonable and customary terms and conditions (consistent with Appendix 1) that are
typical for such a license agreement.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

2

 

5. Access to Information. During the Japan Option Term, Valeant shall keep Schering reasonably
informed as to the status of development of Taribavirin in the Territory by or on behalf of Valeant
or its third party licensees. Schering shall have the right, exercisable at any time after [**]
but prior to the expiration of the Japan Option Term, to conduct a full due diligence review of any
and all data and information generated by or on behalf of Valeant and/or any of its Affiliates,
licensees or partners, in connection with the development of Taribavirin products in the Territory.
Upon request by Schering, Valeant shall provide, and shall ensure that its Affiliates, licensees
and/or partners provide, Schering’s employees, consultants and/or representatives with reasonable
access to such data and information as is necessary to enable Schering to complete such due
diligence review. Following completion of such due diligence review, Valeant shall, upon request
during the remainder of the Japan Option Term, provide Schering with (1) an update of any
additional material information related to the safety or efficacy of Taribavirin that is generated,
and (2) copies of any substantive communications with the FDA or EMEA regarding an NDA or other
application for marketing authorization approval for Taribavirin in the Territory.

6. Confidentiality. Schering acknowledges and agrees that all information and data received or
otherwise made available to it under Section 5 is confidential and proprietary information of
Valeant and/or its licensees or partners. Schering hereby represents, warrants and covenants that
Schering and its Affiliates will use such information and data for the sole purpose of evaluating
its rights to exercise the Japan Option. Upon expiration of the Japan Option Term, Schering shall
upon request promptly return to Valeant or, at the request of Valeant, destroy all information and
data received under Section 5. This section 6 shall survive the termination or expiration of the
Japan Option Term and the Term of this Agreement for any reason.

7. Exclusivity Covenant. Valeant hereby represents, warrants and covenants that during the Japan
Option Term it shall not, and shall ensure that its Affiliates do not, license, sell, transfer,
assign or convey to any third party or to otherwise encumber any rights or interests in or to
Taribavirin in Japan (including without limitation (i) any related Japanese patents, patent
applications or trademarks, and (ii) any rights in Japan to use trade secrets, data, know-how,
information or other intellectual property rights to Taribavirin and/or the manufacture or use of
Taribavirin) that are owned or controlled by Valeant and/or its Affiliates. Valeant shall ensure
that any licenses or other rights or interests with respect to Taribavirin that it or its
Affiliates grants or conveys to any third party during the Japan Option Term are consistent with
the foregoing exclusivity covenants, the rights granted to Schering under Sections 3, 4 and 5 of
this Agreement, and the terms and conditions for the Japan License Agreement that are set forth in
Appendix 1.

8. Publicity. Schering and Valeant shall agree on the form, content and timing of any initial
press releases concerning this Agreement which the Parties intend to issue as soon as practicable
after the Effective Date. In the event that either Party intends to issue any subsequent press
release,
public announcements or other further public disclosures relating to this Agreement, the terms and
conditions hereof, and/or the performance by the Parties hereunder, it shall provide the other
Party with a copy of its proposed release or public disclosure for review and comment at least two
(2) business days prior to the planned disclosure, and shall give due consideration to any comments

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

3

 

received from such Party. Nothing in the foregoing, however, shall prohibit a Party from making
disclosures to the extent necessary under applicable federal or state securities laws or any rule
or regulation of any nationally recognized securities exchange, provided that (i) the
disclosure is accurate and complete, (ii) the disclosing Party shall where applicable, request
confidential treatment to the extent available, and (iii) the disclosing Party shall provide copies
of the proposed disclosure reasonably in advance of such filing or other disclosure for the other
Party’s prior review and comment and shall give due consideration to any comments by such other
Party relating to such filing, including without limitation the provisions of this Agreement for
which confidential treatment should be sought. In addition, Valeant shall have the right to
disclose in strict confidence the terms and conditions of this Agreement as necessary to its
prospective licensees of rights to Taribavirin in the Territory.

9. Termination. Except as otherwise expressly set forth in this Section 9, this Agreement and all
of the Parties’ respective rights and obligations set forth herein shall terminate as follows:

	 	(i)	 	Solely in the event that Schering exercises the Japan Option prior to
expiration of the Japan Option Term, effective as of the effective date of the Japan
License Agreement as contemplated herein; or
	 
	 	(ii)	 	in the event that Schering fails to exercise the Japan Option prior to the
expiration of the Japan Option Term, effective upon the expiration of the Japan Option
Term, and Schering and its Affiliates shall thereafter have no further rights or
interests of any kind whatsoever with respect to Taribavirin.

This Agreement shall not be otherwise terminable except by mutual written agreement of the Parties.
For the avoidance of doubt, the waiver and release granted by Schering under Section 2 shall not
be terminable under any circumstances and shall survive the termination or expiration of this
Agreement for any reason.

10. Miscellaneous Provisions.

10.1 Relationship of the Parties. Each Party is an independent contractor, and nothing
herein shall be construed as creating an employee/employer, agency, partnership or joint
venturer relationship between any of the Parties. None of the Parties shall have the
authority to speak for, represent, bind or obligate another Party in any way without the
prior express written authority of such other Party.

10.2 Force Majeure. If any Party shall be delayed, interrupted in or prevented from the
performance of any obligation hereunder by reason of force majeure including an act of God,
fire, flood, earthquake, war (declared or undeclared), public disaster, act of terrorism,
strike or labor differences, governmental enactment, rule or regulation, or any other cause

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

4

 

beyond such Party’s control, such Party shall not be liable to the other Parties therefor;
and the time for performance of such obligation shall be extended for a period equal to the
duration of the force majeure which occasioned the delay, interruption or prevention. The
Party invoking such force majeure rights shall use commercially reasonable efforts to
overcome such force majeure event and resume performance as soon as possible;
provided that nothing herein shall be construed as obligating a Party to settle on
terms unsatisfactory to such Party any strike, lock-out or other labor difficulty, any
investigation or proceeding by any public authority, or any litigation by any third party.

10.3 Notice. All notices, consents, requests, waivers and other communications required or
permitted under this Agreement shall be in writing and sent by personal delivery, fax (with
confirmation copy), internationally recognized courier, or certified or registered mail,
postage prepaid (airmail where applicable) to the receiving Party at the address or fax
number, as applicable, set forth below, or any replacement address or fax number notified to
the sender by notice actually received by such Party:

If to Valeant:

	 	 	 
	 

	 	Valeant Pharmaceuticals International
	 

	 	One Enterprise
	 

	 	Aliso Viejo, CA 92656
	 
	 	 
	 

	 	Attention: CEO
	 

	 	Fax: 949-461-6661
	 
	 	 
	 

	 	with a copy to:
	 
	 	 
	 

	 	Attention: General Counsel
	 

	 	Fax: 949-315-3818

If to Schering:

	 	 	 
	 

	 	Schering Corporation
	 

	 	2000 Galloping Hill Road
	 

	 	Kenilworth, NJ 07033
	 

	 	Attention: Vice President, Business Development
	 

	 	Fax:
	 
	 	 
	 

	 	with a copy to:

	 	 	 	 	 
	 

	 	Attention:
	 	Sr. Legal Director,
	 

	 	 	 	Business Development & Strategic Alliances
	 

	 	Fax:	 	 

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

5

 

10.4 Further Assurances. Except as expressly provided elsewhere in this Agreement, each
Party will at its expense promptly execute and deliver any further instruments and documents
and take any further action as the other Party may reasonably request in order to give
effect to the terms and conditions of this Agreement.

10.5 Waiver. A Party may, by written instrument executed by such Party, extend the time for
the performance of any obligations of the other Party, waive any inaccuracies and
representations by the other Party in this Agreement or in any document delivered pursuant
to this Agreement or waive compliance by the other Party with any of the covenants,
conditions or performance of any of its obligations under this Agreement. Any such waiver
or failure to insist upon strict compliance with such covenant, condition or obligation will
not operate as a waiver of, or estoppel with respect to, any subsequent or other failure.

10.6 Entire Agreement/Amendments. This Agreement, together with the attached Appendix 1 and
the November 2000 Agreement, constitutes the entire understanding and agreement between the
Parties with respect to its subject matter and, upon the Effective Date, supersedes all
prior discussions, negotiations, correspondence, agreements, and understandings, both oral
and written, between the Parties with respect thereto. This Agreement may not be altered or
otherwise amended except by an instrument in writing signed by each of the Parties.

10.7 Construction. The Parties have participated jointly in the negotiation and drafting of
this Agreement. If a question of intent or interpretation arises, this Agreement will be
construed as if drafted jointly by the Parties and no presumption or burden of proof will
arise favoring or disfavoring a Party because of the authorship of any provision of this
Agreement.

10.8 Counterparts. This Agreement may be executed in any number of counterparts and by
facsimile, each of which will be deemed to be an original and all of which together will
constitute one and the same agreement.

10.9 Severability. If any provision of this Agreement is finally determined to be invalid,
unlawful or incapable of being enforced in a jurisdiction, (i) it will be deemed to be
severed from this Agreement in such jurisdiction, (ii) every other provision of this
Agreement will remain in full force and effect in such jurisdiction, (iii) the Parties will
negotiate in good faith to modify this Agreement so as to achieve the original intent of the
Parties as closely as possible in an acceptable manner with respect to such jurisdiction and
(iv) such invalidity, unlawfulness or unenforceability will not affect the interpretation or
enforcement of this Agreement in any other jurisdiction.

10.10 Governing Law. This Agreement will be governed by and construed in accordance with
the laws of the State of New York, USA, without regard to its principles regarding conflicts
of law.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

6

 

IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized
representatives as of the dates set forth below.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	SCHERING CORPORATION	 	 	 	VALEANT PHARMACEUTICALS	 	 
	 	 	 	 	 	 	 	 	INTERNATIONAL	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	 	 	By:	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Name:	 	David A Piacquad	 	 	 	Name:	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Title:	 	Vice President,	 	 	 	Title:	 	 	 	 
	 

	 	 	 	Business Development	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Date:

	 	 	 	 	 	 	 	Date:	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	SCHERING-PLOUGH LTD.	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Name:	 	David A. Piacquad	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Title:	 	Managing Officer	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Date:
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

7

 

Appendix 1

Terms and Conditions for the Japan License Agreement

Any Japan License Agreement entered into by the Parties or their respective Affiliates shall
include and be otherwise consistent with the following terms and conditions:

	 	1	 	Valeant will grant to Schering (or its designated Affiliate) an exclusive (even as to
Valeant) license in Japan to develop, import, market, promote, distribute, offer for sale
and sell pharmaceutical products containing Taribavirin. In furtherance of that license,
Valeant will also grant Schering (or its designated Affiliate) a non-exclusive worldwide
license to (i) make, have made, import or export Taribavirin and pharmaceutical products
containing Taribavirin solely for the purpose of developing and commercializing such
products in Japan, and (ii) conduct pre-clinical and/or clinical studies and/or other
development activities using Taribavirin solely for purposes of obtaining and maintaining
health registrations and/or supporting commercialization of Taribavirin products in Japan.
These licenses will encompass all relevant patents, patent applications, data, information
and know-how owned or controlled by Valeant and/or its Affiliates related to Taribavirin or
the manufacture and/or use thereof.
	 
	 	2	 	Valeant will also grant to Schering (or its designated Affiliates) the rights to
cross-reference, access and utilize any US NDAs and EU marketing authorizations for [**]
that are held by Valeant, its Affiliates, licensees or partners. Such rights shall be
solely for the purpose of developing and commercializing Taribavirin products (including
monotherapy and combination products) in Japan, including without limitation to obtain and
maintain regulatory approvals in Japan, and to manufacture Taribavirin anywhere in the
world solely for use and/or sale in Japan.
	 
	 	3	 	Schering will grant to Valeant (or its designated Affiliates) the rights to
cross-reference, access and utilize any marketing authorizations for [**] that are held by
Schering, its Affiliates, licensees or partners. Such rights shall be solely for the
purpose of developing and commercializing Taribavirin products (including monotherapy and
combination products) in the Territory, including without limitation to obtain and maintain
regulatory approvals in any and all countries in the Territory, and to manufacture
Taribavirin anywhere in the world solely for use and/or sale in the Territory.
	 
	 	4	 	Schering will control, be responsible for, and bear the full cost and expense of, the
development and commercialization of Taribavirin in Japan.
	 
	 	5	 	The Japan License Agreement shall provide for Schering (or its designated Affiliate) to
pay to Valeant the following compensation in consideration for the licenses and other
rights granted under that agreement:

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

8

 

	 	(i)	 	a one time, up-front, license fee in the amount of two million US
dollars ($2,000,000); and
	 
	 	(ii)	 	a royalty of [**] on net sales of pharmaceutical products
containing Taribavirin in Japan by or on behalf of Schering (or its designated
Affiliate). Royalties will be paid quarterly and the term of the royalty
obligation (not to exceed the longer of the life of relevant Valeant patents in
Japan and a term of [**]) will be agreed to by the Parties and set forth in the
Japan License Agreement.

The Japan License Agreement will not include any other up-front payments, license fees,
milestone payments or other compensation.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

9exv4w2

 

    Exhibit 4.2

 

    ACTEL
    CORPORATION

    

 

    1993
    EMPLOYEE STOCK PURCHASE PLAN

    

 

    Amended
    and Restated as of April 23, 2009

    

    

 

    The following constitute the provisions of the 1993 Employee
    Stock Purchase Plan of Actel Corporation.

 

    1.  Purpose.  The purpose of
    the Plan is to provide employees of the Company and its
    Designated Subsidiaries with an opportunity to purchase Common
    Stock of the Company through accumulated payroll deductions. It
    is the intention of the Company that the Plan qualify as an
    “Employee Stock Purchase Plan” under Section 423
    of the Code. The provisions of the Plan, accordingly, shall be
    construed so as to extend and limit participation in a manner
    consistent with the requirements of that section of the Code.

 

    2.  Definitions.

 

    (a) “Board” shall mean the Board of
    Directors of the Company.

 

    (b) “Code” shall mean the Internal
    Revenue Code of 1986, as amended.

 

    (c) “Common Stock” shall mean the
    Common Stock of the Company.

 

    (d) “Company” shall mean Actel
    Corporation, a California corporation.

 

    (e) “Compensation” shall mean all
    base straight time gross earnings including commissions,
    overtime and shift premiums, and all incentive compensation,
    incentive payments, bonuses and other compensation.

 

    (f) “Designated Subsidiaries” shall
    mean the Subsidiaries which have been designated by the Board
    from time to time in its sole discretion as eligible to
    participate in the Plan.

 

    (g) “Employee” shall mean any
    individual who is an employee of the Company or any Designated
    Subsidiary for tax purposes whose employment with the Company or
    any Designated Subsidiary averages at least twenty
    (20) hours per week and more than five (5) months in
    any calendar year. For purposes of the Plan, the employment
    relationship shall be treated as continuing intact while the
    individual is on sick leave or other leave of absence approved
    by the Company. Where the period of leave exceeds 90 days
    and the individual’s right to reemployment is not
    guaranteed either by statute or by contract, the employment
    relationship will be deemed to have terminated on the
    91st day of such leave.

 

    (h) “Enrollment Date” shall mean
    the first day of each Offering Period.

 

    (i) “Exercise Date” shall mean the
    last day of each Offering Period.

 

    (j) “Fair Market Value” shall mean,
    as of any date, the value of Common Stock determined as follows:

 

    (i) If the Common Stock is listed on any established stock
    exchange or a national market system, including without
    limitation the National Market System of the National
    Association of Securities Dealers, Inc. Automated Quotation
    (“NASDAQ”) System, its Fair Market Value shall be the
    closing sale price for the Common Stock (or the mean of the
    closing bid and asked prices, if no sales were reported), as
    quoted on such exchange (or the exchange with the greatest
    volume of trading in Common Stock) or system on the date of such
    determination, as reported in the Wall Street Journal or such
    other source as the Board deems reliable, or;

 

    (ii) If the Common Stock is quoted on the NASDAQ system
    (but not on the National Market System thereof) or is regularly
    quoted by a recognized securities dealer but selling prices are
    not reported, its Fair Market Value shall be the mean of the
    closing bid and asked prices for the Common Stock on the date of
    such determination, as reported in the Wall Street Journal or
    such other source as the Board deems reliable, or;

 

    (iii) In the absence of an established market for the
    Common Stock, the Fair Market Value thereof shall be determined
    in good faith by the Board.

    

    1

 

    (k) “Offering Period” shall mean
    the period of approximately twenty-four (24) months during
    which an option granted pursuant to the Plan may be exercised.
    Offering Periods shall commence on the first Trading Day on or
    after August 1 and February 1 of each year and terminate on the
    last Trading Day of the periods ending twenty-four
    (24) months later. The duration and timing of Offering
    Periods may be changed pursuant to Sections 4 and 19 of
    this Plan.

 

    (l) “Plan” shall mean this Employee
    Stock Purchase Plan.

 

    (m) “Purchase Period” shall mean
    the approximately six month period commencing after one Exercise
    Date and ending with the next Exercise Date, except that the
    first Purchase Period of any Offering Period shall commence on
    the Enrollment Date and end with the next Exercise Date.

 

    (n) “Purchase Price” shall mean an
    amount equal to 85% of the Fair Market Value of a share of
    Common Stock on the Enrollment Date or on the Exercise Date,
    whichever is lower.

 

    (o) “Reserves” shall mean the
    number of shares of Common Stock covered by each option under
    the Plan which have not yet been exercised and the number of
    shares of Common Stock which have been authorized for issuance
    under the Plan but not yet placed under options.

 

    (p) “Subsidiary” shall mean a
    corporation, domestic or foreign, of which not less than 50% of
    the voting shares are held by the Company or a Subsidiary,
    whether or not such corporation now exists or is hereafter
    organized or acquired by the Company or a Subsidiary.

 

    (q) “Trading Day” shall mean a day
    on which national stock exchanges and the National Association
    of Securities Dealers Automated Quotation (NASDAQ) System are
    open for trading.

 

    3.  Eligibility.

 

    (a) Any Employee (as defined in Section 2(g)), who
    shall be employed by the Company on a given Enrollment Date
    shall be eligible to participate in the Plan.

 

    (b) Any provisions of the Plan to the contrary
    notwithstanding, no Employee shall be granted an option under
    the Plan (i) if immediately after the grant, such Employee
    (or any other person whose stock would be attributed to such
    Employee pursuant to Section 424(d) of the Code) would own
    capital stock of the Company
    and/or hold
    outstanding options to purchase such stock possessing five
    percent (5%) or more of the total combined voting power or value
    of all classes of the capital stock of the Company or of any
    Subsidiary, or (ii) which permits his or her rights to
    purchase stock under all employee stock purchase plans of the
    Company and its subsidiaries to accrue at a rate which exceeds
    twenty-five thousand dollars ($25,000) of Fair Market Value of
    such stock (determined at the time such option is granted) for
    each calendar year in which such option is outstanding at any
    time.

 

    4.  Offering Periods.  The
    Plan shall be implemented by consecutive Offering Periods.
    Offering Periods shall commence on the first Trading Day on or
    after February 1 and August 1 of each year and terminate on the
    last Trading Day of the periods ending twenty-four months later.
    The Board shall have the power to change the duration of
    Offering Periods (including the commencement dates thereof) with
    respect to future offerings without shareholder approval if such
    change is announced at least five (5) days prior to the
    scheduled beginning of the first Offering Period to be affected.

 

    5.  Participation.

 

    (a) An eligible Employee may become a participant in the
    Plan by completing a subscription agreement authorizing payroll
    deductions (in the form of Exhibit A to this Plan) and
    filing it with the Company’s payroll office prior to the
    applicable Enrollment Date.

 

    (b) Payroll deductions for a participant shall commence on
    the first payroll following the Enrollment Date and shall end on
    the last payroll in the Offering Period to which such
    authorization is applicable, unless sooner terminated by the
    participant as provided in Section 10 hereof.

    

    2

 

    6.  Payroll Deductions.

 

    (a) At the time a participant files his or her subscription
    agreement, he or she shall elect to have payroll deductions made
    on each pay day during the Offering Period in an amount not
    exceeding fifteen percent (15%) of the Compensation which he or
    she receives on each pay day during the Offering Period, and the
    aggregate of such payroll deductions during the Offering Period
    shall not exceed fifteen percent (15%) of the participant’s
    Compensation during said Offering Period; provided,
    however, that a participant’s total payroll deductions
    used to purchase stock under the Plan in any calendar year shall
    not exceed ten thousand dollars ($10,000).

 

    (b) All payroll deductions made for a participant shall be
    credited to his or her account under the Plan and will be
    withheld in whole percentages only. A participant may not make
    any additional payments into such account.

 

    (c) A participant may discontinue his or her participation
    in the Plan as provided in Section 10 hereof, or may
    decrease the rate of his or her payroll deductions during the
    Offering Period by filing with the Company a new subscription
    agreement authorizing a change in payroll deduction rate. A
    participant may not increase the rate of his or her payroll
    deductions during a Purchase Period. The Board may, in its
    discretion, limit the number of participation rate changes
    during any Offering Period. The change in rate shall be
    effective with the first full payroll period following five
    (5) business days after the Company’s receipt of the
    new subscription agreement unless the Company elects to process
    a given change in participation more quickly. A
    participant’s subscription agreement shall remain in effect
    for successive Offering Periods unless terminated as provided in
    Section 10 hereof.

 

    (d) Notwithstanding the foregoing, to the extent necessary
    to comply with Section 423(b)(8) of the Code and
    Section 3(b) hereof, a participant’s payroll
    deductions may be decreased to 0% if the following should occur:
    For the Purchase Periods that end during a single calendar year,
    the sum of all payroll deductions that have been used to
    purchase stock under the Plan plus all payroll deductions
    accumulated for the purchase of stock equals $21,250. Payroll
    deductions shall recommence at the rate provided in such
    participant’s subscription agreement at the beginning of
    the first Purchase Period which is scheduled to end in the
    subsequent calendar year, unless terminated by the participant
    as provided in Section 10 hereof.

 

    (e) At the time the option is exercised, in whole or in
    part, or at the time some or all of the Company’s Common
    Stock issued under the Plan is disposed of, the participant must
    make adequate provision for the Company’s federal, state,
    or other tax withholding obligations, if any, which arise upon
    the exercise of the option or the disposition of the Common
    Stock. At any time, the Company may, but will not be obligated
    to, withhold from the participant’s compensation the amount
    necessary for the Company to meet applicable withholding
    obligations, including any withholding required to make
    available to the Company any tax deductions or benefits
    attributable to sale or early disposition of Common Stock by the
    Employee.

 

    7.  Grant of Option.  On the
    Enrollment Date of each Offering Period, each eligible Employee
    participating in such Offering Period shall be granted an option
    to purchase on the Exercise Date of such Offering Period (at the
    applicable Purchase Price) up to a number of shares of the
    Company’s Common Stock determined by dividing such
    Employee’s payroll deductions accumulated prior to such
    Exercise Date and retained in the Participant’s account as
    of the Exercise Date by the applicable Purchase Price; provided
    that such purchase shall be subject to the limitations set forth
    in Sections 3(b) and 12 hereof; provided, further, that in
    no event shall any Employee purchase in excess of ten thousand
    shares in any Offering Period. Exercise of the option shall
    occur as provided in Section 8 hereof, unless the
    participant has withdrawn pursuant to Section 10 hereof,
    and the option shall expire on the last day of the Offering
    Period.

 

    8.  Exercise of
    Option.  Unless a participant withdraws from
    the Plan as provided in Section 10 hereof, his or her
    option for the purchase of shares will be exercised
    automatically on the Exercise Date, and the maximum number of
    full shares subject to the option shall be purchased for such
    participant at the applicable Purchase Price with the
    accumulated payroll deductions in his or her account. No
    fractional shares will be purchased; any payroll deductions
    accumulated in a participant’s account which are not
    sufficient to purchase a full share shall be retained in the
    participant’s account for the subsequent Purchase Period,
    subject to earlier withdrawal by the participant as provided in
    Section 10 hereof. Any other monies left over in a
    participant’s account after the Exercise Date shall be
    returned to the participant. During a participant’s
    lifetime, a participant’s option to purchase shares
    hereunder is exercisable only by him or her.

    3

 

    9.  Delivery.  As promptly as
    practicable after each Exercise Date on which a purchase of
    shares occurs, the Company shall arrange the delivery to each
    participant, as appropriate, of a certificate representing the
    shares purchased upon exercise of his or her option.

 

    10.  Withdrawal; Termination of
    Employment.

 

    (a) A participant may withdraw all but not less than all
    the payroll deductions credited to his or her account and not
    yet used to exercise his or her option under the Plan at any
    time by giving written notice to the Company in the form of
    Exhibit B to this Plan. All of the participant’s
    payroll deductions credited to his or her account will be paid
    to such participant promptly after receipt of notice of
    withdrawal and such participant’s option for the Offering
    Period will be automatically terminated, and no further payroll
    deductions for the purchase of shares will be made during the
    Offering Period. If a participant withdraws from an Offering
    Period, payroll deductions will not resume at the beginning of
    the succeeding Offering Period unless the participant delivers
    to the Company a new subscription agreement.

 

    (b) Upon a participant’s ceasing to be an Employee (as
    defined in Section 2(g) hereof), for any reason, he or she
    will be deemed to have elected to withdraw from the Plan and the
    payroll deductions credited to such participant’s account
    during the Offering Period but not yet used to exercise the
    option will be returned to such participant or, in the case of
    his or her death, to the person or persons entitled thereto
    under Section 14 hereof, and such participant’s option
    will be automatically terminated.

 

    11.  Interest.  No interest
    shall accrue on the payroll deductions of a participant in the
    Plan.

 

    12.  Stock.

 

    (a) The maximum number of shares of the Company’s
    Common Stock which shall be made available for sale under the
    Plan shall be 6,519,680 shares, subject to adjustment upon
    changes in capitalization of the Company as provided in
    Section 18 hereof. If on a given Exercise Date the number
    of shares with respect to which options are to be exercised
    exceeds the number of shares then available under the Plan, the
    Company shall make a pro rata allocation of the shares remaining
    available for purchase in as uniform a manner as shall be
    practicable and as it shall determine to be equitable.

 

    (b) The participant will have no interest or voting right
    in shares covered by his option until such option has been
    exercised.

 

    (c) Shares to be delivered to a participant under the Plan
    will be registered in the name of the participant or in the name
    of the participant and his or her spouse.

 

    13.  Administration.

 

    (a) Administrative Body.  The Plan
    shall be administered by the Board or a committee of members of
    the Board appointed by the Board. The Board or its committee
    shall have full and exclusive discretionary authority to
    construe, interpret and apply the terms of the Plan, to
    determine eligibility and to adjudicate all disputed claims
    filed under the Plan. Every finding, decision and determination
    made by the Board or its committee shall, to the full extent
    permitted by law, be final and binding upon all parties. Members
    of the Board who are eligible Employees are permitted to
    participate in the Plan, provided that:

 

    (i) Members of the Board who are eligible to participate in
    the Plan may not vote on any matter affecting the administration
    of the Plan or the grant of any option pursuant to the Plan.

 

    (ii) If a Committee is established to administer the Plan,
    no member of the Board who is eligible to participate in the
    Plan may be a member of the Committee.

 

    (b) Rule 16b-3
    Limitations.  Notwithstanding the provisions
    of Subsection (a) of this Section 13, in the event
    that
    Rule 16b-3
    promulgated under the Securities Exchange Act of 1934, as
    amended (the “Exchange Act”), or any successor
    provision
    (“Rule 16b-3”)
    provides specific requirements for the administrators of plans
    of this type, the Plan shall be only administered by such a body
    and in such a manner as shall comply with the applicable
    requirements of
    Rule 16b-3.
    Unless permitted by
    Rule 16b-3,
    no discretion concerning decisions regarding the Plan shall be
    afforded to any committee or person that is not
    “disinterested” as that term is used in
    Rule 16b-3.

    4

 

    14.  Designation of Beneficiary.

 

    (a) A participant may file a written designation of a
    beneficiary who is to receive any shares and cash, if any, from
    the participant’s account under the Plan in the event of
    such participant’s death subsequent to an Exercise Date on
    which the option is exercised but prior to delivery to such
    participant of such shares and cash. In addition, a participant
    may file a written designation of a beneficiary who is to
    receive any cash from the participant’s account under the
    Plan in the event of such participant’s death prior to
    exercise of the option. If a participant is married and the
    designated beneficiary is not the spouse, spousal consent shall
    be required for such designation to be effective.

 

    (b) Such designation of beneficiary may be changed by the
    participant at any time by written notice. In the event of the
    death of a participant and in the absence of a beneficiary
    validly designated under the Plan who is living at the time of
    such participant’s death, the Company shall deliver such
    shares
    and/or cash
    to the executor or administrator of the estate of the
    participant, or if no such executor or administrator has been
    appointed (to the knowledge of the Company), the Company, in its
    discretion, may deliver such shares
    and/or cash
    to the spouse or to any one or more dependents or relatives of
    the participant, or if no spouse, dependent or relative is known
    to the Company, then to such other person as the Company may
    designate.

 

    15.  Transferability.  Neither
    payroll deductions credited to a participant’s account nor
    any rights with regard to the exercise of an option or to
    receive shares under the Plan may be assigned, transferred,
    pledged or otherwise disposed of in any way (other than by will,
    the laws of descent and distribution or as provided in
    Section 14 hereof) by the participant. Any such attempt at
    assignment, transfer, pledge or other disposition shall be
    without effect, except that the Company may treat such act as an
    election to withdraw funds from an Offering Period in accordance
    with Section 10 hereof.

 

    16.  Use of Funds.  All
    payroll deductions received or held by the Company under the
    Plan may be used by the Company for any corporate purpose, and
    the Company shall not be obligated to segregate such payroll
    deductions.

 

    17.  Reports.  Individual
    accounts will be maintained for each participant in the Plan.
    Statements of account will be given to participating Employees
    at least annually, which statements will set forth the amounts
    of payroll deductions, the Purchase Price, the number of shares
    purchased and the remaining cash balance, if any.

 

    18.  Adjustments Upon Changes in
    Capitalization.

 

    (a) Changes in
    Capitalization.  Subject to any required
    action by the shareholders of the Company, the Reserves as well
    as the price per share of Common Stock covered by each option
    under the Plan which has not yet been exercised shall be
    proportionately adjusted for any increase or decrease in the
    number of issued shares of Common Stock resulting from a stock
    split, reverse stock split, stock dividend, combination or
    reclassification of the Common Stock, or any other increase or
    decrease in the number of shares of Common Stock effected
    without receipt of consideration by the Company; provided,
    however, that conversion of any convertible securities of the
    Company shall not be deemed to have been “effected without
    receipt of consideration”. Such adjustment shall be made by
    the Board, whose determination in that respect shall be final,
    binding and conclusive. Except as expressly provided herein, no
    issuance by the Company of shares of stock of any class, or
    securities convertible into shares of stock of any class, shall
    affect, and no adjustment by reason thereof shall be made with
    respect to, the number or price of shares of Common Stock
    subject to an option.

 

    (b) Dissolution or Liquidation.  In
    the event of the proposed dissolution or liquidation of the
    Company, the Offering Periods will terminate immediately prior
    to the consummation of such proposed action, unless otherwise
    provided by the Board.

 

    (c) Merger or Asset Sale.  In the
    event of a proposed sale of all or substantially all of the
    assets of the Company, or the merger of the Company with or into
    another corporation, each option under the Plan shall be assumed
    or an equivalent option shall be substituted by such successor
    corporation or a parent or subsidiary of such successor
    corporation, unless the Board determines, in the exercise of its
    sole discretion and in lieu of such assumption or substitution,
    to shorten the Offering Periods then in progress by setting a
    new Exercise Date (the “New Exercise Date”) or to
    cancel each outstanding option to purchase and refund all sums
    collected from participants during the Offering Period then in
    progress. If the Board shortens the Offering Periods then in
    progress

    5

 

    in lieu of assumption or substitution in the event of a merger
    or sale of assets, the Board shall notify each participant in
    writing, at least ten (10) business days prior to the New
    Exercise Date, that the Exercise Date for his option has been
    changed to the New Exercise Date and that his option will be
    exercised automatically on the New Exercise Date, unless prior
    to such date he has withdrawn from the Offering Period as
    provided in Section 10 hereof. For purposes of this
    paragraph, an option granted under the Plan shall be deemed to
    be assumed if, following the sale of assets or merger, the
    option confers the right to purchase, for each share of stock
    subject to the option immediately prior to the sale of assets or
    merger, the consideration (whether stock, cash or other
    securities or property) received in the sale of assets or merger
    by holders of Common Stock for each share of Common Stock held
    on the effective date of the transaction (and if such holders
    were offered a choice of consideration, the type of
    consideration chosen by the holders of a majority of the
    outstanding shares of Common Stock); provided, however, that if
    such consideration received in the sale of assets or merger was
    not solely common stock of the successor corporation or its
    parent (as defined in Section 424(e) of the Code), the
    Board may, with the consent of the successor corporation and the
    participant, provide for the consideration to be received upon
    exercise of the option to be solely common stock of the
    successor corporation or its parent equal in fair market value
    to the per share consideration received by holders of Common
    Stock and the sale of assets or merger.

 

    The Board may, if it so determines in the exercise of its sole
    discretion, also make provision for adjusting the Reserves, as
    well as the price per share of Common Stock covered by each
    outstanding option, in the event the Company effects one or more
    reorganizations, recapitalizations, rights offerings or other
    increases or reductions of shares of its outstanding Common
    Stock, and in the event of the Company being consolidated with
    or merged into any other corporation.

 

    19.  Amendment or Termination.

 

    (a) The Board of Directors of the Company may at any time
    and for any reason terminate or amend the Plan. Except as
    provided in Sections 18 and 19 hereof, no such termination
    can affect options previously granted, provided that outstanding
    and/or
    future Offering Periods may be shortened
    and/or
    terminated by the Board of Directors at any time. Except as
    provided in Section 18 hereof and in the preceding
    sentence, no amendment may make any change in any option
    theretofore granted which adversely affects the rights of any
    participant. To the extent necessary to comply with
    Rule 16b-3
    or under Section 423 of the Code (or any successor rule or
    provision or any other applicable law or regulation), the
    Company shall obtain shareholder approval in such a manner and
    to such a degree as required.

 

    (b) Without shareholder consent and without regard to
    whether any participant rights may be considered to have been
    “adversely affected,” the Board (or its committee)
    shall be entitled to change the Offering Periods, limit the
    frequency
    and/or
    number of changes in the amount withheld during an Offering
    Period, establish the exchange ratio applicable to amounts
    withheld in a currency other than U.S. dollars, permit
    payroll withholding in excess of the amount designated by a
    participant in order to adjust for delays or mistakes in the
    Company’s processing of properly completed withholding
    elections, establish reasonable waiting and adjustment periods
    and/or
    accounting and crediting procedures to ensure that amounts
    applied toward the purchase of Common Stock for each participant
    properly correspond with amounts withheld from the
    participant’s Compensation, and establish such other
    limitations or procedures as the Board (or its committee)
    determines in its sole discretion advisable which are consistent
    with the Plan.

 

    (c) In the event the Board (or its committee) determines
    that the ongoing operation of the Plan may result in unfavorable
    financial accounting consequences, the Board (or its committee)
    may, in its discretion and, to the extent necessary or
    desirable, modify or amend the Plan to reduce or eliminate such
    accounting consequence including, but not limited to:

 

    (i) amending the Plan to conform with the safe harbor
    definition under Statement of Financial Accounting Standards 123
    (revised December 2004), including with respect to an Offering
    Period underway at the time;

 

    (ii) altering the Purchase Price for any Offering Period
    including an Offering Period underway at the time of the change
    in Purchase Price;

    6

 

    (iii) shortening any Offering Period so that Offering
    Period ends on a new Exercise Date, including an Offering Period
    underway at the time of the Board action;

 

    (iv) reducing the maximum percentage of Compensation a
    Participant may elect to set aside as payroll deductions;

 

    (v) reducing the maximum number of Shares a Participant may
    purchase during any Offering Period; and

 

    (vi) allocating shares.

 

    Such modifications or amendments shall not require shareholder
    approval or the consent of any Plan participants.

 

    20.  Notices.  All notices or
    other communications by a participant to the Company under or in
    connection with the Plan shall be deemed to have been duly given
    when received in the form specified by the Company at the
    location, or by the person, designated by the Company for the
    receipt thereof.

 

    21.  Conditions Upon Issuance of
    Shares.  Shares shall not be issued with
    respect to an option unless the exercise of such option and the
    issuance and delivery of such shares pursuant thereto shall
    comply with all applicable provisions of law, domestic or
    foreign, including, without limitation, the Securities Act of
    1933, as amended, the Securities Exchange Act of 1934, as
    amended, the rules and regulations promulgated thereunder, and
    the requirements of any stock exchange upon which the shares may
    then be listed, and shall be further subject to the approval of
    counsel for the Company with respect to such compliance.

 

    As a condition to the exercise of an option, the Company may
    require the person exercising such option to represent and
    warrant at the time of any such exercise that the shares are
    being purchased only for investment and without any present
    intention to sell or distribute such shares if, in the opinion
    of counsel for the Company, such a representation is required by
    any of the aforementioned applicable provisions of law.

 

    22.  Term of Plan.  The Plan
    became effective on the date on which the Company’s
    registration statement on
    Form S-1
    (or any successor form thereof) is declared effective by the
    Securities and Exchange Commission. It shall continue in effect
    until August 2, 2013, unless sooner terminated under
    Section 19 hereof.

 

    23.  Additional Restrictions of
    Rule 16b-3.  The
    terms and conditions of options granted hereunder to, and the
    purchase of shares by, persons subject to Section 16 of the
    Exchange Act shall comply with the applicable provisions of
    Rule 16b-3.
    This Plan shall be deemed to contain, and such options shall
    contain, and the shares issued upon exercise thereof shall be
    subject to, such additional conditions and restrictions as may
    be required by
    Rule 16b-3
    to qualify for the maximum exemption from Section 16 of the
    Exchange Act with respect to Plan transactions.

 

    24.  Automatic Transfer to Low Price Offering
    Period.  To the extent permitted by
    Rule 16b-3
    of the Securities Exchange Act of 1934, as amended, if the Fair
    Market Value of the Common Stock on any Exercise Date in an
    Offering Period is lower than the Fair Market Value of the
    Common Stock on the Enrollment Date of such Offering Period,
    then all participants in such Offering Period shall be
    automatically withdrawn from such Offering Period immediately
    after the exercise of their options on such Exercise Date and
    automatically re-enrolled in the immediately following Offering
    Period as of the first day thereof.

    7

 

 

    EXHIBIT A

    

 

    ACTEL
    CORPORATION

    

 

    1993
    EMPLOYEE STOCK PURCHASE PLAN

 

    SUBSCRIPTION
    AGREEMENT

 

		
	                   
    Original
    Application
    	      Enrollment
    Date:                    
    

 

                   
    Change in Payroll Deduction Rate

 

                   
    Change of Beneficiary (or Beneficiaries)

 

    1.                                                                                                             hereby elects to participate in the Actel Corporation 1993
    Employee Stock Purchase Plan (the “Employee Stock Purchase
    Plan”) and subscribes to purchase shares of the
    Company’s Common Stock in accordance with this Subscription
    Agreement and the Employee Stock Purchase Plan.

 

    2. I hereby authorize payroll deductions from each paycheck
    in the amount of
              %
    of my Compensation on each payday (not to exceed 15%) during the
    Offering Period in accordance with the Employee Stock Purchase
    Plan. (Please note that no fractional percentages are
    permitted.) In no event will the total payroll deductions used
    to purchase shares of the Company’s Common Stock in
    accordance with this Subscription Agreement and the Employee
    Stock Purchase Plan in any calendar year exceed $10,000.

 

    3. I understand that said payroll deductions shall be
    accumulated for the purchase of shares of Common Stock at the
    applicable Purchase Price determined in accordance with the
    Employee Stock Purchase Plan. I understand that if I do not
    withdraw from an Offering Period, any accumulated payroll
    deductions will be used to automatically exercise my option.

 

    4. I have received a copy of the complete “Actel
    Corporation 1993 Employee Stock Purchase Plan.” I
    understand that my participation in the Employee Stock Purchase
    Plan is in all respects subject to the terms of the Plan. I
    understand that the grant of the option by the Company under
    this Subscription Agreement is subject to obtaining shareholder
    approval of the Employee Stock Purchase Plan.

 

    5. Shares purchased for me under the Employee Stock
    Purchase Plan should be issued in the name(s) of (Employee or
    Employee and Spouse
    Only):                                                                  
                                                                                                           

 

    6. I understand that if I dispose of any shares received by
    me pursuant to the Plan within 2 years after the Enrollment
    Date (the first day of the Offering Period during which I
    purchased such shares) or one year after the Exercise Date, I
    will be treated for federal income tax purposes as having
    received ordinary income at the time of such disposition in an
    amount equal to the excess of the fair market value of the
    shares at the time such shares were purchased over the price
    which I paid for the shares. I hereby agree to notify the
    Company in writing within 30 days after the date of any
    disposition of my shares and I will make adequate provision for
    Federal, state or other tax withholding obligations, if any,
    which arise upon the disposition of the Common Stock.
    The Company may, but will not be obligated to, withhold from my
    compensation the amount necessary to meet any applicable
    withholding obligation including any withholding necessary to
    make available to the Company any tax deductions or benefits
    attributable to sale or early disposition of Common Stock by me.
    If I dispose of such shares at any time after the expiration of
    the 2-year
    and 1-year
    holding periods, I understand that I will be treated for federal
    income tax purposes as having received income only at the time
    of such disposition, and that such income will be taxed as
    ordinary income only to the extent of an amount equal to the
    lesser of (1) the excess of the fair market value of the
    shares at the time of such disposition over the purchase price
    which I paid for the shares, or (2) 15% of the fair market
    value of the shares on the first day of the Offering Period. The
    remainder of the gain, if any, recognized on such disposition
    will be taxed as capital gain.

 

    7. I hereby agree to be bound by the terms of the Employee
    Stock Purchase Plan. The effectiveness of this Subscription
    Agreement is dependent upon my eligibility to participate in the
    Employee Stock Purchase Plan.

 

    8. In the event of my death, I hereby designate the
    following as my beneficiary to receive all payments and shares
    due me under the Employee Stock Purchase Plan (if you wish to
    designate more than one beneficiary, execute and deliver copies
    of this page):

    8

 

    PLEASE PRINT!

 

    NAME:
     ­
    ­

			
	                        (First)
    	     (Middle)
    	     (Last)
    

 

	 	 	 
	

    
                    Relationship

	
 
	
    

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
    (Address)

 

    I UNDERSTAND THAT THIS SUBSCRIPTION AGREEMENT SHALL REMAIN IN
    EFFECT THROUGHOUT SUCCESSIVE OFFERING PERIODS UNLESS TERMINATED
    BY ME.

 

	 	 	 
	

    Dated: ­
    ­

	
 
	
    

    Signature
    of Employee

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
    Spouse’s Signature

    (If beneficiary other than spouse)

    9

 

    EXHIBIT B

    

 

    ACTEL
    CORPORATION

    

 

    1993
    EMPLOYEE STOCK PURCHASE PLAN

    

 

    NOTICE OF
    WITHDRAWAL

 

    The undersigned participant in the Offering Period of the Actel
    Corporation 1993 Employee Stock Purchase Plan which began
    on                    ,
    20          
    (the “Enrollment Date”) hereby notifies the Company
    that he or she hereby withdraws from the Offering Period. He or
    she hereby directs the Company to pay to the undersigned as
    promptly as practicable all the payroll deductions credited to
    his or her account with respect to such Offering Period. The
    undersigned understands and agrees that his or her option for
    such Offering Period will be automatically terminated. The
    undersigned understands further that no further payroll
    deductions will be made for the purchase of shares in the
    current Offering Period and the undersigned shall be eligible to
    participate in succeeding Offering Periods only by delivering to
    the Company a new Subscription Agreement.

 

	 	 	 
	
 
	
 
	
    

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
    (Name and Address of Participant)

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
    (Signature)

	
 
	
 
	
 

	
 
	
 
	
    

	
 
	
 
	
    (Date)

    10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]